Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Analysts

Compass Therapeutics, Inc. (NASDAQ:CMPX) has been assigned a consensus rating of “Moderate Buy” from the fourteen ratings firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, eleven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $12.9091.

A number of brokerages have issued reports on CMPX. Wall Street Zen cut Compass Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Stifel Nicolaus set a $6.00 target price on Compass Therapeutics in a report on Monday, June 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Therapeutics in a report on Monday, April 20th. Citigroup reaffirmed a “market outperform” rating on shares of Compass Therapeutics in a report on Thursday. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $9.00 target price on shares of Compass Therapeutics in a report on Thursday, March 5th.

Hedge Funds Weigh In On Compass Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CMPX. Strs Ohio bought a new position in shares of Compass Therapeutics during the first quarter worth about $34,000. Creative Planning bought a new stake in Compass Therapeutics in the second quarter valued at approximately $30,000. XTX Topco Ltd bought a new stake in Compass Therapeutics in the second quarter valued at approximately $84,000. Invesco Ltd. boosted its holdings in Compass Therapeutics by 58.1% in the second quarter. Invesco Ltd. now owns 58,735 shares of the company’s stock valued at $153,000 after acquiring an additional 21,578 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its holdings in Compass Therapeutics by 11.3% in the second quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company’s stock valued at $11,505,000 after acquiring an additional 449,868 shares during the last quarter. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Price Performance

Shares of CMPX stock opened at $2.04 on Monday. Compass Therapeutics has a twelve month low of $1.61 and a twelve month high of $6.88. The company has a market cap of $367.38 million, a P/E ratio of -4.98 and a beta of 0.89. The business has a fifty day simple moving average of $3.49 and a 200 day simple moving average of $4.86.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). As a group, equities research analysts anticipate that Compass Therapeutics will post -0.42 earnings per share for the current fiscal year.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.